Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics

Asian Journal of Psychiatry · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles